CYTOSAR

This brand name is authorized in Estonia, Hong Kong, Croatia, Mexico, Poland, South Africa

Active ingredients

The drug CYTOSAR contains one active pharmaceutical ingredient (API):

1 Cytarabine UNII 04079A1RDZ - CYTARABINE

Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes. Read about Cytarabine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CYTOSAR Powder for solution for injection	Health Products Regulatory Authority (ZA)	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01BC01	Cytarabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1001383, 1001451, 1001530
Country: HK	Department of Health Drug Office	Identifier(s): 27972, 29543
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-301692413
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 74316
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100016481, 100016498, 100016506, 100396383, 100396390
Country: ZA	Health Products Regulatory Authority	Identifier(s): T/26/47, T/26/48